<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p170" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_170{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_170{left:306px;bottom:30px;}
#t3_170{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_170{left:346px;bottom:30px;}
#t5_170{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_170{left:517px;bottom:30px;}
#t7_170{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_170{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_170{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_170{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_170{left:35px;bottom:777px;letter-spacing:0.1px;word-spacing:0.09px;}
#tc_170{left:35px;bottom:754px;letter-spacing:0.17px;word-spacing:-0.8px;}
#td_170{left:35px;bottom:731px;letter-spacing:0.12px;word-spacing:0.07px;}
#te_170{left:35px;bottom:707px;letter-spacing:0.18px;}
#tf_170{left:35px;bottom:684px;letter-spacing:0.18px;word-spacing:0.01px;}
#tg_170{left:35px;bottom:661px;letter-spacing:0.05px;word-spacing:0.14px;}
#th_170{left:35px;bottom:638px;letter-spacing:0.01px;word-spacing:0.02px;}
#ti_170{left:35px;bottom:614px;letter-spacing:0.11px;word-spacing:-1.16px;}
#tj_170{left:516px;bottom:614px;letter-spacing:0.24px;word-spacing:-1.28px;}
#tk_170{left:35px;bottom:591px;letter-spacing:0.17px;word-spacing:0.02px;}
#tl_170{left:155px;bottom:591px;letter-spacing:0.12px;word-spacing:0.07px;}
#tm_170{left:35px;bottom:554px;letter-spacing:-0.1px;word-spacing:0.52px;}
#tn_170{left:35px;bottom:529px;letter-spacing:0.24px;word-spacing:-0.05px;}
#to_170{left:35px;bottom:507px;letter-spacing:0.14px;word-spacing:0.05px;}
#tp_170{left:35px;bottom:484px;letter-spacing:0.23px;word-spacing:-0.05px;}
#tq_170{left:372px;bottom:484px;letter-spacing:0.19px;}
#tr_170{left:35px;bottom:460px;letter-spacing:0.19px;}
#ts_170{left:282px;bottom:460px;letter-spacing:0.12px;word-spacing:0.07px;}
#tt_170{left:35px;bottom:437px;letter-spacing:0.15px;word-spacing:0.04px;}
#tu_170{left:35px;bottom:414px;letter-spacing:0.22px;word-spacing:-0.74px;}
#tv_170{left:35px;bottom:391px;letter-spacing:0.18px;word-spacing:-0.81px;}
#tw_170{left:35px;bottom:368px;letter-spacing:0.12px;word-spacing:0.06px;}
#tx_170{left:442px;bottom:368px;letter-spacing:0.26px;word-spacing:-0.07px;}
#ty_170{left:35px;bottom:344px;letter-spacing:0.17px;word-spacing:-1.21px;}
#tz_170{left:335px;bottom:344px;letter-spacing:0.15px;word-spacing:0.04px;}
#t10_170{left:35px;bottom:321px;letter-spacing:0.05px;word-spacing:0.14px;}
#t11_170{left:35px;bottom:281px;letter-spacing:0.12px;word-spacing:0.07px;}
#t12_170{left:35px;bottom:258px;letter-spacing:0.2px;word-spacing:-0.01px;}
#t13_170{left:35px;bottom:234px;letter-spacing:0.09px;word-spacing:-1.14px;}
#t14_170{left:35px;bottom:211px;letter-spacing:0.15px;word-spacing:0.04px;}
#t15_170{left:35px;bottom:188px;letter-spacing:0.12px;word-spacing:-0.56px;}
#t16_170{left:35px;bottom:165px;letter-spacing:0.01px;word-spacing:-0.24px;}
#t17_170{left:188px;bottom:165px;letter-spacing:0.18px;word-spacing:-1.22px;}
#t18_170{left:453px;bottom:165px;letter-spacing:0.09px;word-spacing:-0.53px;}
#t19_170{left:35px;bottom:141px;letter-spacing:0.06px;word-spacing:-1.1px;}
#t1a_170{left:35px;bottom:118px;letter-spacing:0.12px;word-spacing:0.07px;}
#t1b_170{left:337px;bottom:118px;letter-spacing:0.19px;}
#t1c_170{left:35px;bottom:95px;letter-spacing:0.19px;}
#t1d_170{left:282px;bottom:95px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1e_170{left:35px;bottom:72px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1f_170{left:154px;bottom:79px;letter-spacing:0.1px;}
#t1g_170{left:618px;bottom:777px;letter-spacing:0.31px;}
#t1h_170{left:618px;bottom:748px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1i_170{left:618px;bottom:724px;letter-spacing:0.09px;word-spacing:-1.13px;}
#t1j_170{left:843px;bottom:724px;letter-spacing:0.13px;word-spacing:-0.29px;}
#t1k_170{left:618px;bottom:701px;letter-spacing:0.08px;}
#t1l_170{left:618px;bottom:660px;letter-spacing:-0.17px;word-spacing:1.03px;}
#t1m_170{left:618px;bottom:632px;letter-spacing:0.17px;word-spacing:-0.09px;}
#t1n_170{left:618px;bottom:608px;letter-spacing:0.05px;word-spacing:0.13px;}
#t1o_170{left:618px;bottom:585px;letter-spacing:0.18px;}
#t1p_170{left:618px;bottom:562px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1q_170{left:618px;bottom:539px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1r_170{left:618px;bottom:515px;letter-spacing:0.07px;word-spacing:-1.12px;}
#t1s_170{left:618px;bottom:492px;letter-spacing:0.13px;word-spacing:0.06px;}
#t1t_170{left:1084px;bottom:500px;letter-spacing:0.61px;}
#t1u_170{left:1099px;bottom:492px;letter-spacing:0.19px;word-spacing:-0.01px;}
#t1v_170{left:618px;bottom:469px;letter-spacing:-0.02px;word-spacing:-0.1px;}
#t1w_170{left:878px;bottom:477px;letter-spacing:-0.01px;}
#t1x_170{left:901px;bottom:469px;letter-spacing:0.1px;word-spacing:0.09px;}
#t1y_170{left:618px;bottom:446px;letter-spacing:0.1px;word-spacing:0.08px;}
#t1z_170{left:618px;bottom:423px;letter-spacing:0.19px;}
#t20_170{left:782px;bottom:423px;letter-spacing:0.11px;}
#t21_170{left:841px;bottom:423px;}
#t22_170{left:618px;bottom:382px;letter-spacing:0.32px;word-spacing:-0.13px;}
#t23_170{left:618px;bottom:353px;letter-spacing:0.08px;word-spacing:0.11px;}
#t24_170{left:618px;bottom:330px;letter-spacing:-0.03px;word-spacing:-0.67px;}
#t25_170{left:618px;bottom:308px;letter-spacing:0.27px;}
#t26_170{left:658px;bottom:308px;letter-spacing:0.12px;word-spacing:0.06px;}
#t27_170{left:826px;bottom:308px;letter-spacing:0.13px;word-spacing:0.06px;}
#t28_170{left:618px;bottom:284px;letter-spacing:0.13px;word-spacing:0.05px;}
#t29_170{left:618px;bottom:261px;letter-spacing:0.14px;word-spacing:-0.33px;}
#t2a_170{left:618px;bottom:238px;letter-spacing:0.01px;word-spacing:0.18px;}
#t2b_170{left:1116px;bottom:238px;letter-spacing:0.18px;}
#t2c_170{left:618px;bottom:215px;letter-spacing:0.25px;word-spacing:-0.06px;}
#t2d_170{left:834px;bottom:215px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2e_170{left:618px;bottom:192px;letter-spacing:0.09px;}
#t2f_170{left:693px;bottom:199px;letter-spacing:0.1px;}
#t2g_170{left:618px;bottom:151px;letter-spacing:0.06px;word-spacing:0.13px;}
#t2h_170{left:618px;bottom:128px;letter-spacing:0.12px;word-spacing:0.06px;}
#t2i_170{left:618px;bottom:105px;letter-spacing:0.08px;word-spacing:-0.75px;}
#t2j_170{left:618px;bottom:82px;letter-spacing:0.11px;word-spacing:0.08px;}
#t2k_170{left:618px;bottom:58px;letter-spacing:0.16px;word-spacing:0.02px;}
#t2l_170{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_170{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_170{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_170{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_170{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_170{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_170{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s6_170{font-size:16px;font-family:Arial-BoldItalicMT_kg;color:#000;}
.s7_170{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s8_170{font-size:20px;font-family:Arial-BoldMT_5te;color:#000;}
.s9_170{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts170" type="text/css" >

@font-face {
	font-family: Arial-BoldItalicMT_kg;
	src: url("fonts/Arial-BoldItalicMT_kg.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg170Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg170" style="-webkit-user-select: none;"><object width="1210" height="935" data="170/170.svg" type="image/svg+xml" id="pdf170" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_170" class="t s0_170">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_170" class="t s1_170">© </span>
<span id="t3_170" class="t s0_170">(NCCN </span>
<span id="t4_170" class="t s1_170">© </span>
<span id="t5_170" class="t s0_170">), All rights reserved. NCCN Guidelines </span>
<span id="t6_170" class="t s1_170">® </span>
<span id="t7_170" class="t s0_170">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_170" class="t s2_170">NCCN Guidelines Version 4.2024 </span>
<span id="t9_170" class="t s2_170">Head and Neck Cancers </span>
<span id="ta_170" class="t s3_170">MS-29 </span>
<span id="tb_170" class="t s4_170">positive or close margins are the same, but re-resection is an option if </span>
<span id="tc_170" class="t s4_170">technically feasible, although challenging after free-tissue reconstruction. </span>
<span id="td_170" class="t s4_170">Consideration of subsequent EBRT is also an option, while the potential </span>
<span id="te_170" class="t s4_170">role of brachytherapy in this scenario is under explored (see section on </span>
<span id="tf_170" class="t s4_170">Radiation Therapy, below). For other risk features—such as pT3 or pT4 </span>
<span id="tg_170" class="t s4_170">primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, </span>
<span id="th_170" class="t s4_170">perineural invasion, vascular invasion, or lymphatic invasion—RT alone is </span>
<span id="ti_170" class="t s4_170">recommended, or systemic therapy/RT may be considered (see </span><span id="tj_170" class="t s5_170">Cancer of </span>
<span id="tk_170" class="t s5_170">the Oral Cavity </span><span id="tl_170" class="t s4_170">in the NCCN Guidelines for Head and Neck Cancers). </span>
<span id="tm_170" class="t s6_170">Radiation Therapy </span>
<span id="tn_170" class="t s4_170">If definitive RT is chosen for treatment of T1–2, N0 disease, the fraction </span>
<span id="to_170" class="t s4_170">size to the intermediate- and low-risk sites ranges from 44 Gy (2.0 </span>
<span id="tp_170" class="t s4_170">Gy/fraction) to 63 Gy (1.6 Gy/fraction) (see </span><span id="tq_170" class="t s5_170">Cancer of the Oral Cavity: </span>
<span id="tr_170" class="t s5_170">Principles of Radiation Therapy </span><span id="ts_170" class="t s4_170">in the NCCN Guidelines for Head and </span>
<span id="tt_170" class="t s4_170">Neck Cancers). For these sites of suspected subclinical spread, </span>
<span id="tu_170" class="t s4_170">suggested doses are 44–50 Gy if 3D-CRT is used or 54–63 Gy if IMRT is </span>
<span id="tv_170" class="t s4_170">used, depending on the dose/fraction (1.6–2.0 Gy/fraction). Doses of 66– </span>
<span id="tw_170" class="t s4_170">70 Gy are adequate to control high-risk disease (see </span><span id="tx_170" class="t s5_170">Cancer of the Oral </span>
<span id="ty_170" class="t s5_170">Cavity: Principles of Radiation Therapy </span><span id="tz_170" class="t s4_170">in the NCCN Guidelines for Head </span>
<span id="t10_170" class="t s4_170">and Neck Cancers). </span>
<span id="t11_170" class="t s4_170">RT, when used as definitive treatment, may consist of EBRT with (or </span>
<span id="t12_170" class="t s4_170">without) brachytherapy, depending on the size of the tumor. </span>
<span id="t13_170" class="t s4_170">Brachytherapy should only be performed at centers with expertise but may </span>
<span id="t14_170" class="t s4_170">be an option for select situations (eg, close or positive margins after </span>
<span id="t15_170" class="t s4_170">surgical resection with flap reconstruction). Supportive studies have been </span>
<span id="t16_170" class="t s4_170">limited in scale (see </span><span id="t17_170" class="t s5_170">Head and Neck Radiation Therapy </span><span id="t18_170" class="t s4_170">in this Discussion, </span>
<span id="t19_170" class="t s4_170">above). The NCCN algorithm provides recommendations for low dose-rate </span>
<span id="t1a_170" class="t s4_170">and high dose-rate brachytherapy (see </span><span id="t1b_170" class="t s5_170">Cancer of the Oral Cavity: </span>
<span id="t1c_170" class="t s5_170">Principles of Radiation Therapy </span><span id="t1d_170" class="t s4_170">in the NCCN Guidelines for Head and </span>
<span id="t1e_170" class="t s4_170">Neck Cancers). </span>
<span id="t1f_170" class="t s7_170">412,413 </span>
<span id="t1g_170" class="t s3_170">Follow-up/Surveillance </span>
<span id="t1h_170" class="t s4_170">Recommendations for surveillance are provided in the algorithm (see </span>
<span id="t1i_170" class="t s5_170">Follow-up Recommendations </span><span id="t1j_170" class="t s4_170">in the NCCN Guidelines for Head and Neck </span>
<span id="t1k_170" class="t s4_170">Cancers). </span>
<span id="t1l_170" class="t s8_170">Cancer of the Oropharynx </span>
<span id="t1m_170" class="t s4_170">The oropharynx includes the base of the tongue, tonsils, soft palate, and </span>
<span id="t1n_170" class="t s4_170">pharyngeal wall. The oropharynx is extremely rich in lymphatics. </span>
<span id="t1o_170" class="t s4_170">Depending on the subsite involved, 15% to 75% of patients present with </span>
<span id="t1p_170" class="t s4_170">lymph node involvement. Oropharyngeal cancer that is p16-positive (ie, </span>
<span id="t1q_170" class="t s4_170">HPV-mediated) is a different disease than p16-negative cancer. To take </span>
<span id="t1r_170" class="t s4_170">into account these differences, separate staging criteria were published for </span>
<span id="t1s_170" class="t s4_170">p16-negative and p16-positive oropharyngeal cancer in the 8 </span>
<span id="t1t_170" class="t s7_170">th </span>
<span id="t1u_170" class="t s4_170">edition of </span>
<span id="t1v_170" class="t s4_170">the AJCC Cancer Staging Manual. </span>
<span id="t1w_170" class="t s7_170">391 </span>
<span id="t1x_170" class="t s4_170">In 2018, the panel created separate </span>
<span id="t1y_170" class="t s4_170">algorithms for p16-positive (HPV-mediated) oropharyngeal cancer. See </span>
<span id="t1z_170" class="t s4_170">the section below on </span><span id="t20_170" class="t s5_170">Staging</span><span id="t21_170" class="t s4_170">. </span>
<span id="t22_170" class="t s3_170">Workup and Staging </span>
<span id="t23_170" class="t s4_170">A multidisciplinary consultation is encouraged including a registered </span>
<span id="t24_170" class="t s4_170">dietitian and a speech-language/swallowing therapist as clinically indicated </span>
<span id="t25_170" class="t s4_170">(see </span><span id="t26_170" class="t s5_170">Principles of Nutrition </span><span id="t27_170" class="t s4_170">in the NCCN Guidelines for Head and Neck </span>
<span id="t28_170" class="t s4_170">Cancers). Accurate staging (see Table 3 for p16-negative oropharyngeal </span>
<span id="t29_170" class="t s4_170">cancer and Table 4 for p16-positive oropharyngeal cancer) depends on a </span>
<span id="t2a_170" class="t s4_170">complete H&amp;N examination and appropriate imaging studies (see </span><span id="t2b_170" class="t s5_170">Cancer </span>
<span id="t2c_170" class="t s5_170">of the Oropharynx: Workup </span><span id="t2d_170" class="t s4_170">in NCCN Guidelines for Head and Neck </span>
<span id="t2e_170" class="t s4_170">Cancers). </span>
<span id="t2f_170" class="t s7_170">391,414 </span>
<span id="t2g_170" class="t s4_170">The panel recommends examination under anesthesia (EUA) with biopsy </span>
<span id="t2h_170" class="t s4_170">confirmation for patients presenting with a p16-positive cervical lymph </span>
<span id="t2i_170" class="t s4_170">node prior to treatment decision-making. There may be situations in which </span>
<span id="t2j_170" class="t s4_170">the EUA is undesirable or could be bypassed. These include patients at </span>
<span id="t2k_170" class="t s4_170">high risk for general anesthesia and those who undergo a thorough </span>
<span id="t2l_170" class="t s9_170">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
